Jeff Black

CFO

Boston Scientific Corp (BSX)

CFO

Alphatec Holdings, Inc. (ATEC)

CFO

Standard Biotools Inc. (LAB)

CFO

Exagen Inc. (XGN)

Equibles does not estimate personal net worth.

Get an email with a short summary when Boston Scientific Corp publishes a filing, an earnings call transcript or a press release.

Get BSX alerts

About Jeff Black

Jeff Black is recorded as CFO at Boston Scientific Corp (BSX), CFO at Alphatec Holdings, Inc. (ATEC), CFO at Standard Biotools Inc. (LAB) and CFO at Exagen Inc. (XGN). Jeff Black has spoken on 10 earnings calls and 1 other investor event across 4 companies, most recently for Exagen Inc. on August 11, 2026. Those appearances were for Exagen Inc. (XGN), Standard Biotools Inc. (LAB), Boston Scientific Corp (BSX) and Alphatec Holdings, Inc. (ATEC). Exagen Inc. is classified in the Diagnostics & Research industry within the Healthcare sector. Standard Biotools Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Exagen Inc. includes John Aballi (CEO, CFO and Board Member), Tina S. Nova (Chairman), Jeffrey Black (CFO) and 7 others.

Jeff Black on recent calls

“Yeah, I would just say, Carl, we had talked about this before, but the whole concept of excess cash, meaning if we're collecting over the accrual rate, then that's going to hit revenue in any given quarter.”

CFO, Canaccord Genuity Growth Conference · August 11, 2026

“2026 is off to a solid start with first quarter results reflecting continued deliberate execution across the business. Once again, we achieved record top-line performance by growth in both testing volume and ASP.”

CFO, Exagen Inc. Q1 FY2026 Earnings Call · May 11, 2026

“2025 is off to a strong and exciting start. We are eager to keep building on this momentum throughout the year. We've made great progress on our financial objectives over the past quarter.”

CFO, Exagen Inc. Q1 FY2025 Earnings Call · May 5, 2025

“I first want to say a few words about my decision to leave Standard BioTools. Since I started the company almost 15 months ago, we've set an incredibly strong foundation for transformation.”

CFO, Standard Biotools Inc. Q2 FY2024 Earnings Call · July 31, 2024

“As a reminder, unless otherwise noted, the 2023 financial results we reported today reflect only the Standard BioTools legacy business and exclude the results of SomaLogic, which will be included for the first time with our first quarter results.”

CFO, Standard Biotools Inc. Q4 FY2023 Earnings Call · January 8, 2024